Cardio therapeutic heart sack
AssigneeAcorn Cardiovascular, Inc.
InventorYUZI OKUZUMI
Life of this patent
Estimating the term…
Loading patent…
AssigneeAcorn Cardiovascular, Inc.
InventorYUZI OKUZUMI
Estimating the term…
This invention relates to implantable heart sack that can be equipped with pacemaker leads and/or defibrillation leads for the treatment of cardiomyopathy, hypertrophic cardiomyopathy, tachycardia, bradycardia, ventricular fibrillation, atrial fibrillation etc. The hear sack was prepared from biocompatible, biostable, implantable polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane, polyfluoroethylene, or hydrogenated poly(styrene-butadiene) copolymer. The heart sack is equipped with attached sutures to make it easier to attach onto the heart. The heart sack can be made semipermeable or perforated to have numerous holes. The heart sack can be reinforce with fiber or filament. Ordinary pacemaker leads can be attached to the inner side of the heart sack. However, the pacemaker leads of this invention were prepared from noble metal (gold, platinum, rhodium and platinum-Rhodium alloys) or stainless steel coated, deposited or plated mono-filaments, yarns, braids, cords, wires or films, or cylindrical tubes of polyamide, polyimide, polyester, and/or polypropylene that are encased in multi-lumen insulating tube or coaxial tube made of biocompatible, biostable, implantable polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane, polyfluoroethylene, or hydrogenated poly(styrene-butadiene) copolymer. The leads can be mounted onto the inner surface of the heart sack and contoured to the heart. The heart sack can be coated with hydrophilic coating containing an antimicrobial agent that gives the heart sack a low coefficient of friction, excellent biocompatibility and antimicrobial properties.
An implantable heart sack for the treatment of heart ailment that is prepared from biocompatible, biostable and implantable elastomers selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane, polyfluoroethylene, ethylene propylene terpolymer, or hydrogenated poly(styrene-butadiene) copolymer and has holes and grooves for the pulmonary artery, aorta, other blood vessels, the pacemaker leads, defibrillation leads or other therapy devices and has slits which enable to the heart sack to wrap around the heart and blood vessels.
An implantable heart sack for the treatment of heart ailment that is prepared from biocompatible, biostable and implantable elastomers selected from the group consisting of polyetherurethane, polycarbonateurethane, silicone, polysiloxaneurethane, polyfluoroethylene, ethylene propylene terpolymer, or hydrogenated poly(styrene-butadiene) copolymer and the said heart sack is reinforced with the biocompatible, biostable and implantable braids, cords, fibers, monofilament, wires, yams, cloth, woven fabric, non-woven fabrics or elastomers prepared from the group consisting of polyamide, polyimide, polyester, polypropylene, and polyurethane, and has holes and grooves for the pulmonary artery, aorta, other blood vessels, pacemaker leads, defibrillation leads, and other therapy devices and has slits which enable to the heart sack to wrap around the heart and blood vessels and is equipped or can be equipped with either pacemaker leads, defibrillation leads or both;
A method to make semipermeable heart sack membrane by coating and drying a heart shaped model with appropriate blood vessel features and have holes and grooves for the pacemaker leads or defibirillation leads or both, with a mixture of polyethylene glycol (PEG) having a molecular weight of from 200 to 5,000 with the elastomer solution prepared from the reaction of polytetramethylene ether glycol having a molecular weight range of from 400 to 3,000 and methylene bis(p-phenylisocyanate) with the molar ratio of 1 to 1.6 to 1.9 respectively in N,N' dimethylacetoamide (DMA) at temperature range of from 50° C. to 90° C., then adding a mixture of ethylene diamine, 1,3 diaminocyclohexane and diethylamine in DMA (1:0.24:0.19 molar ratio respectively) to chain extend to obtain 5% to 40% solution, and adding 0.001 to 0.1% of a stabilizer;
Dependencies are inferred from the claim text.